MediciNova, Inc.
Methods and dosing regimens using ibudilast and a second agent for cancer therapy
Last updated:
Abstract:
Methods and dosing regimens for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof and at least one or more other therapeutic agent.
Status:
Grant
Type:
Utility
Filling date:
10 Jul 2020
Issue date:
20 Sep 2022